Abatacept Monotherapy Versus Abatacept Plus Methotrexate for Treatment-Refractory Rheumatoid Arthritis

被引:8
作者
Pascart, Tristan [1 ,2 ,3 ]
Philippe, Peggy [2 ]
Drumez, Elodie [4 ]
Deprez, Xavier [5 ]
Cortet, Bernard [2 ,3 ]
Duhamel, Alain [4 ]
Houvenagel, Eric [1 ]
Flipo, Rene-Marc [2 ]
机构
[1] Univ Lille, St Philibert Hosp, Dept Rheumatol, Lomme Les Lille, France
[2] Univ Hosp Lille, Dept Rheumatol, Lille, France
[3] Univ Hosp Lille, EA 4490, Lille, France
[4] Univ Lille, CHRU Lille, Dept Biostat, EA2694, Lille, France
[5] Valenciennes Hosp, Dept Rheumatol, Valenciennes, France
关键词
rheumatoid arthritis; abatacept; methotrexate; monotherapy; TNFi inadequate response; INTERIM ANALYSIS; BIOLOGICS; RITUXIMAB; EFFICACY; SAFETY;
D O I
10.1097/MJT.0000000000000645
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Methotrexate combination therapy improves abatacept efficacy as a first-line biologic agent for the treatment of rheumatoid arthritis, but it is unclear when abatacept is used later on, particularly after non-TNF inhibitor (TNFi) failure. Study Question: The objective of this study was to determine whether treatment response after nonTNFi inadequate response is different in patients with rheumatoid arthritis (RA) treated with abatacept in combination with or not with methotrexate. Methods: Patients treated with abatacept monotherapy or in combination with methotrexate after non-TNFi failure were included. Results: Data from 46 patients aged 56 years [49-61] with 12 years [8-16] of disease duration were examined. Rituximab was the treatment used in the previous line for 75.0% of the combination therapy group (15/20) and 34.6% (9/26) in the monotherapy group. At 12 months, 38.5% (10/26) of patients were in good-to-moderate EULAR response in the monotherapy group compared with 25.0% (5/20) in the combination therapy group (P = 0.33). Treatment persistence at 12 months was 61.5% (16/26) in the monotherapy group and 35.0% (7/20) in the combination therapy group (P =0.07). Conclusions: Adding methotrexate to abatacept did not improve treatment response in patients with RA after non-TNFi inadequate response.
引用
收藏
页码:E358 / E363
页数:6
相关论文
共 50 条
[41]   Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis [J].
Harigai, Masayoshi ;
Ishiguro, Naoki ;
Inokuma, Shigeko ;
Mimori, Tsuneyo ;
Ryu, Junnosuke ;
Takei, Syuji ;
Takeuchi, Tsutomu ;
Tanaka, Yoshiya ;
Takasaki, Yoshinari ;
Yamanaka, Hisashi ;
Watanabe, Masahiko ;
Tamada, Hiroshi ;
Koike, Takao .
MODERN RHEUMATOLOGY, 2016, 26 (04) :491-498
[42]   The Use of Abatacept for the Treatment of Felty Syndrome in Rheumatoid Arthritis [J].
Chin, Rishika, V ;
Serin, Sheila ;
Khan, Ahmed ;
Smith, Keneisha ;
Kumar, Suresh .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
[43]   Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists [J].
Scheinfeld, Noah .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2006, 17 (04) :229-234
[44]   Cancer risk with tocilizumab/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study [J].
Westermann, Rasmus ;
Cordtz, Rene Lindholm ;
Duch, Kirsten ;
Mellemkjaer, Lene ;
Hetland, Merete Lund ;
Magnussen, Bergur ;
Dreyer, Lene .
RHEUMATOLOGY, 2024, 64 (03) :1019-1028
[45]   Abatacept suppresses the telomerase activity of lymphocytes in patients with rheumatoid arthritis [J].
Otani, Kazuhiro ;
Kurosaka, Daitaro .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (06) :1138-1144
[46]   Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency [J].
Lanz, Anna-Lisa ;
Riester, Martin ;
Peters, Philipp ;
Schwerd, Tobias ;
Lurz, Eberhard ;
Hajji, Mohammad Samer ;
Rohlfs, Meino ;
Ley-Zaporozhan, Julia ;
Walz, Christoph ;
Kotlarz, Daniel ;
Klein, Christoph ;
Albert, Michael H. ;
Hauck, Fabian .
CLINICAL IMMUNOLOGY, 2021, 229
[47]   Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis [J].
Piantoni, Silvia ;
Colombo, Enrico ;
Tincani, Angela ;
Airo, Paolo ;
Scarsi, Mirko .
CLINICAL RHEUMATOLOGY, 2016, 35 (04) :1065-1069
[48]   Efficacy and safety of abatacept in patients with rheumatoid arthritis with previous malignancy [J].
Kunishita, Yosuke ;
Ichikawa, Kento ;
Uzawa, Yuji ;
Mitsuhashi, Masaki ;
Yoshioka, Yuji ;
Okubo, Tadanobu ;
Nagaoka, Shouhei .
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2023, 15
[49]   Role of abatacept in the management of rheumatoid arthritis [J].
Nogid, Anna ;
Pham, David Q. .
CLINICAL THERAPEUTICS, 2006, 28 (11) :1764-1778
[50]   Abatacept in the Treatment of Patients With Psoriatic Arthritis [J].
Mease, Philip ;
Genovese, Mark C. ;
Gladstein, Geoffrey ;
Kivitz, Alan J. ;
Ritchlin, Christopher ;
Tak, Paul P. ;
Wollenhaupt, Juergen ;
Bahary, Orna ;
Becker, Jean-Claude ;
Kelly, Sheila ;
Sigal, Leonard ;
Teng, Julie ;
Gladman, Dafna .
ARTHRITIS AND RHEUMATISM, 2011, 63 (04) :939-948